Your browser doesn't support javascript.
loading
Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials
Zhang, Yue; Tao, Li-na; Qu, Xiao-yu; Niu, Jun-qi; Ding, Yan-hua; Zhang, Si-xi.
Affiliation
  • Zhang, Yue; Jilin University. The First Hospital. Department of Pharmacy. Changchun. CN
  • Tao, Li-na; Jilin University. The First Hospital. Department of Pharmacy. Changchun. CN
  • Qu, Xiao-yu; Jilin University. The First Hospital. Department of Pharmacy. Changchun. CN
  • Niu, Jun-qi; Jilin University. The First Hospital. Department of Pharmacy. Changchun. CN
  • Ding, Yan-hua; Jilin University. The First Hospital. Department of Pharmacy. Changchun. CN
  • Zhang, Si-xi; Jilin University. The First Hospital. Department of Pharmacy. Changchun. CN
Rev. Assoc. Med. Bras. (1992, Impr.) ; Rev. Assoc. Med. Bras. (1992, Impr.);64(3): 253-263, Mar. 2018. tab, graf
Article de En | LILACS | ID: biblio-896448
Bibliothèque responsable: BR1.1
ABSTRACT
Summary

Objective:

The aim of this study was to assess the efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs) with meta-analysis method.

Method:

We included six randomized clinical trials identified from Medline, Embase, Cochrane Library, "ISRCTN Register" and "ClinicalTrials.gov" which compared ceftazidime-avibactam with comparison group. The meta-analysis was performed using Review Manager software version 5.3.

Results:

Ceftazidime-avibactam versus active comparisons demonstrated a statistically significant higher rate of microbiological response success on microbiological evaluable populations at the test-of-cure visit (95CI 1.10-2.38, p=0.02) and late-follow-up visit (95CI 1.09-2.23, p=0.02) for the treatment of CUTIs. Ceftazidime-avibactam versus active comparisons demonstrated a statistically significant higher rate of microbiological response success on EME populations at the test-of-cure visit (95CI 1.08-4.27, p=0.03) and late-follow-up visit (OR=1.75, 95CI 1.33-2.29, p<0.0001) for the treatment of CUTIs. Similar results were obtained at the late-follow-up visit (OR = 1.58, 95CI 1.26-1.97, p<0.0001) on microbiologically modified intent-to-treat (mMITT) populations for the treatment of CUTIs. We can find better eradication rates for E. coli and Klebsiella pneumoniae based on mMITT populations. In terms of AEs, SAEs and mortality, ceftazidime-avibactam had a safety and tolerability profile broadly similar to the comparison group.

Conclusion:

This meta-analysis provides evidence of the efficacy of ceftazidime-avibactam as a potential alternative for the treatment of patients with CUTIs, and CIAIs.
Sujet(s)
Mots clés

Texte intégral: 1 Indice: LILACS Sujet Principal: Infections urinaires / Ceftazidime / Composés azabicycliques / Infections intra-abdominales / Antibactériens Type d'étude: Clinical_trials / Systematic_reviews Limites du sujet: Humans langue: En Texte intégral: Rev. Assoc. Med. Bras. (1992, Impr.) Thème du journal: Educa‡Æo em Sa£de / GestÆo do Conhecimento para a Pesquisa em Sa£de / MEDICINA Année: 2018 Type: Article

Texte intégral: 1 Indice: LILACS Sujet Principal: Infections urinaires / Ceftazidime / Composés azabicycliques / Infections intra-abdominales / Antibactériens Type d'étude: Clinical_trials / Systematic_reviews Limites du sujet: Humans langue: En Texte intégral: Rev. Assoc. Med. Bras. (1992, Impr.) Thème du journal: Educa‡Æo em Sa£de / GestÆo do Conhecimento para a Pesquisa em Sa£de / MEDICINA Année: 2018 Type: Article